These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4141280)

  • 1. Phase I study of twice weekly 5-azacytidine (NSC-102816).
    Vogler WR; Arkun S; Velez-Garcia E
    Cancer Chemother Rep; 1974; 58(6):895-9. PubMed ID: 4141280
    [No Abstract]   [Full Text] [Related]  

  • 2. Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study.
    Vélez-Garcia E; Vogler WR; Bartolucci AA; Arkun SN
    Cancer Treat Rep; 1977 Dec; 61(9):1675-7. PubMed ID: 74283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1972 Oct; 56(5):649-52. PubMed ID: 4119908
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).
    Bellet RE; Mastrangelo MJ; Engstrom PF; Strawitz JG; Weiss AJ; Yarbro JW
    Cancer Chemother Rep; 1974; 58(2):217-22. PubMed ID: 4133839
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase I study of 5-azacytidine (NSC-102816).
    Shnider BI; Baig M; Colsky J
    J Clin Pharmacol; 1976 Apr; 16(4):205-12. PubMed ID: 57124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of 5-azacytidine in solid tumors.
    Weiss AJ; Metter GE; Nealon TF; Keanan JP; Ramirez G; Swaiminathan A; Fletcher WS; Moss SE; Manthei RW
    Cancer Treat Rep; 1977; 61(1):55-8. PubMed ID: 67894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of 5-azacytidine in solid tumors.
    Quagliana JM; O'Bryan RM; Baker L; Gottlieb J; Morrison FS; Eyre HJ; Tucker WG; Costanzi J
    Cancer Treat Rep; 1977; 61(1):51-4. PubMed ID: 67893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
    Lomen PL; Khilanani P; Kessel D
    Neoplasma; 1980; 27(1):101-6. PubMed ID: 6154898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271).
    Cunningham TJ; Nemoto T; Rosner D; Knight E; Taylor S; Rosenbaum C; Horton J; Dao T
    Cancer Chemother Rep; 1974; 58(5 Pt 1):677-81. PubMed ID: 4138966
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
    Bellet RE; Catalano RB; Mastrangelo MJ; Berd D
    Med Pediatr Oncol; 1978; 4(1):11-5. PubMed ID: 75498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute leukemia with 5-azacytidine (NSC-102816).
    McCredie KB; Bodey GP; Burgess MA; Gutterman JU; Rodriguez V; Sullivan MP; Freireich EJ
    Cancer Chemother Rep; 1973; 57(3):319-23. PubMed ID: 4127393
    [No Abstract]   [Full Text] [Related]  

  • 12. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
    Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
    Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days.
    Lomen PL; Baker LH; Neil GL; Samson MK
    Cancer Chemother Rep; 1975; 59(6):1123-6. PubMed ID: 56988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nandrolone phenylpropionate (NSC-23162e) on the bone marrow suppression caused by cyclophosphamide (NSC-26271): a clinical trial.
    Burn JI; Cooke WM
    Cancer Chemother Rep; 1974; 58(6):867-70. PubMed ID: 4615786
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy with 5-azacytidine plus beta-2'-deoxythioguanosine in adult acute leukemia.
    Omura GA
    Cancer Treat Rep; 1977 Aug; 61(5):915-7. PubMed ID: 70273
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).
    Creaven PJ; Newman SJ; Selawry OS; Cohen MH; Primack A
    Cancer Chemother Rep; 1974; 58(6):901-7. PubMed ID: 4615787
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-Fluorouracil in childhood solid tumors.
    Haggard ME; Cangir A; Ragab AH; Komp D; Falletta J; Humphrey GB
    Cancer Treat Rep; 1977; 61(1):69-71. PubMed ID: 324621
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination therapy with 5-azacytidine (NSC-102816) and methyl-GAG (NSC-32946) in previously treated adults with acute nonlymphocytic leukemia.
    Levi JA; Wiernik PH
    Cancer Chemother Rep; 1975; 59(5):1043-5. PubMed ID: 54215
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
    Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
    Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
    Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
    Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.